Iambic Therapeutics

California-based Iambic Therapeutics, formerly known as Entos,  provides molecular and materials discovery tools and designs small-molecule therapeutics combining machine learning and automated chemistry via its AI-driven platform, OrbNet. The platform incorporates molecular simulations using quantum mechanics, molecular synthesis, and modeling. It explores multiple profiles in parallel to ensure that the molecules are designed to solve the right problems in disease biology. 

The company’s technology is derived from Caltech and the University of Bristol and aims to accelerate the molecular discovery and design process. Iambic claims it increases the speed and accuracy of molecular properties prediction by a thousand times without the need for custom supercomputers. Additionally, the company claims to reduce computational costs and the quantity of training data required by 100 times. 

Iambic Therapeutics has its internal pipeline of programs which includes: IAM-H1 , a tyrosine kinase inhibitor (TKI) that selectively targets HER2 and HER2 mutants, and IAM-C1 , a small-molecule inhibitor. 

Key customers and partnerships

It has also reportedly secured partnerships with a variety of companies in the pharmaceuticals, materials, and chemicals industries. In October 2023, it partnered with NVIDIA to leverage NVIDIA’s AI platform for drug discovery.

Funding and financials

In October 2023, the company raised USD 100 million in its a Series B funding round co-led by Ascenta Capital and Abingworth to advance multiple AI-discovered candidates into clinical development and expand its pipeline.